pages:
-
ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
-
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
-
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
-
ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
-
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
-
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
-
ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
-
ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
-
ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
-
ADVL1712: A Phase I Trial of Pevonedistat Given in Combination with Fludarabine, Cytarabine, and Azacitidine in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia
-
ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma
-
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
-
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
-
AEIS (Statewide Systems Improvement in Alabama's Early Intervention System)
-
Aerobic Training During or After Adjuvant Therapy: A Randomized Trial
-
AF: Small: Theoretical and Algorithmic Foundations of Constrained Particle Filtering
-
AFC Hazmat Worker Health and Safety Training Cooperative Agreement (U45)
-
Affect of Oxygen Tension on Glioma Stem Cells
-
African American Collaborative Obesity Research Network
-
African American Lesbian Families, Sororities and Fraternities and Their Role in the Promotion of Sexual Health and Prevention of Sexually Transmitted Infections in LGBT Communities
-
African Descent and Glaucoma Evaluation (ADAGES)
-
African Descent and Glaucoma Evaluation (ADAGES) II: Glaucoma Progression
-
African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the Lamina Cribrosa in Progression
-
Age of Blood in Children in Pediatric Intensive Care Unit
-
Age of Blood in Children in Pediatric Intensive Care Units (ABC-PICU)
-
Age Related Differences in Parametrics Response Mapping in COPD (Martinez Supplement)
-
Age- and Race-Related Differences in Optic Nerve Head Structure and Biomechanics
-
Age-Related Changes in Optic Nerve Head Structure and Biomechanics
-
Age-Related Dysbiosis and Physical Resilience
-
Age-Related Macular Degeneration: The Effect of Training on Visual Performance and Neural Activity
pages:
